Pfizer
MSF launches global action against GSK and Pfizer over pneumonia vaccine price
November 12, 2015Manufacturing and Production, Sales and Marketing Doctors Without Borders, GSK, MSF, Médecins Sans Frontières, Pfizer, Synflorix, pneumococcal vaccine, pneumonia, prevenar 13, vaccines
International medical aid charity Médecins Sans Frontières/Doctors Without Borders (MSF) is taking action against GlaxoSmithKline and Pfizer, calling on the …
Pfizer to double patient assistance allowance in the US
November 9, 2015Sales and Marketing Drug pricing, Pfizer
Pfizer says it will double the allowable income level for its RxPathways patient assistance program in the US with immediate …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
Pfizer approached GSK for takeover before Allergan
November 4, 2015Research and Development, Sales and Marketing Allergan, GSK, Pfizer, financial results, product pipeline
Pfizer had a takeover approach rejected by fellow pharma giant GlaxoSmithKline, before turning its attentions to Allergan, it has emerged. …
FDA alleges records cover-up at Chinese Pfizer plant
November 3, 2015Manufacturing and Production FDA, Pfizer, compliance, inspection, manufacturing, production, regulations
The FDA has discovered violations at a Pfizer plant in China, including the use of out-of-date materials and record- keeping …
Pfizer in ‘friendly’ merger talks with Allergan
October 29, 2015Sales and Marketing Actavis, Allergan, Pfizer, Teva
Pfizer is in talks with Allergan over what could be the largest takeover deal in an already record-breaking year, it …
Pfizer’s Xeljanz denied plaque psoriasis indication by FDA
October 16, 2015Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib
The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
Pfizer wins Zoloft birth defects lawsuit
October 12, 2015Sales and Marketing Pfizer, Zoloft, birth defects, lawsuits, sertraline
Judges in the US have dismissed a lawsuit against Pfizer that had claimed that the use of its antidepressant Zoloft during pregnancy …
How can pharma succeed in emerging markets?
October 10, 2015Sales and Marketing GSK, Pfizer
In recent years, the major pharma companies have been forced to react to the maturation and cost-cutting, plus regulatory pressures, …
Pfizer axes lay-off plans and creates new jobs
October 6, 2015Manufacturing and Production Pfizer
A Pfizer facility in Ireland that was set to close has now been taken off the list of facilities no longer needed …
Pfizer completes $130 million purchase of two GSK vaccines
October 5, 2015Sales and Marketing GSK, Pfizer, meningitis
Pfizer has announced that it has completed the $130 million acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. …
Legal analysis: a summary of the Lyrica pregabalin case and the issue of cross-label use in Europe
October 2, 2015Medical Communications Lyrica, Pfizer
The Warner Lambert v Actavis pregabalin cases have been before the UK Courts on no less than seven occasions since the beginning of …
Pfizer’s self-injectable contraceptive becomes UK’s first
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Pfizer, Syayana Press
Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the UK for administration by self-injection following …
Pfizer and GSK in antidepressant safety probes
September 22, 2015Manufacturing and Production GSK, Paxil, Pfizer, Zoloft, antidepressants, drug safety, paroxetine, sertraline
Two top-selling antidepressants have had their safety records challenges, after the FDA asked Pfizer to change the labelling of its …
Pfizer in metabolic disease push
September 11, 2015Medical Communications, Research and Development AMRA, Pfizer, UK Biobank, med tech, metabolic disease, obesity
Pfizer has signed a research collaboration with a global medical health technology company, to investigate risk factors for metabolic conditions. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
